• Users Online: 320
  • Print this page
  • Email this page
Year : 2018  |  Volume : 2  |  Issue : 4  |  Page : 138-141

Prevalence of vitamin D deficiency among libyan chronic kidney disease patients

1 Department of Biochemistry, Faculty of Medicine, University of Benghazi, Benghazi, Libya
2 Department of Medicine, Faculty of Medicine, University of Benghazi, Benghazi, Libya

Correspondence Address:
Dr. Mohamed O Ezwaie
Department of Medicine, Faculty of Medicine, University Benghazi, Benghazi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/LJMS.LJMS_38_18

Rights and Permissions

Background: Vitamin D deficiency is common among patients with chronic kidney disease (CKD). The traditional supplementation of active Vitamin D (1,25–dihydroxyvitamin D (or 1-hydroxyvitamin D to CKD patients has been reported to control the level of secondary hyperparathyroidism but not sufficient to replenish the body store of Vitamin D (25-hydroxyvitamin D). Patients and Methods: We conducted a cross-sectional analysis of two major parameters, namely 25-hydroxyvitamin D and parathyroid hormone (PTH) levels, in 50 female and 30 male CKD patients, compared to a control group of 29 individuals. Aim: The aim of the study was to determine the prevalence of Vitamin D deficiency in different stages of Libyan CKD patients. Moreover, this study aimed to evaluate the prevalence of Vitamin D deficiency in those treated patients compared to untreated ones and also to compare the effect of Vitamin D treatment on Vitamin D and PTH levels. Results: The mean 25(OH) Vitamin D level in CKD patients was 18.45 (±13.6) ng/ml, whereas for the healthy control, it was 19.03 (±11.49) ng/ml. The level of 25(OH) Vitamin D <20 ng/ml was observed in 80.6% of untreated patients and hence classified as deficient, whereas only 69% of the involved healthy controls were found to be Vitamin D deficient. However, on treatment, the prevalence of Vitamin D deficiency in patients had declined to 30.8%. Furthermore, PTH level in Vitamin D-treated patients was 118.56 ± 38 pg/dl, while in untreated, it was 393.77 ± 46 pg/dl; this significant lowering effect on PTH level was not produced on treating patients with 1-hydroxyvitamin D alone, as the mean of PTH was 436.48 ± 62.55 pg/dl in the treated patients and 324.96 ± 67.61 pg/dl in untreated patients. Furthermore, no significant differences in the levels of 25(OH) Vitamin D were detected among patients who representing the different stages of CKD. Nevertheless, gender has no significant effect on 25(OH Vitamin D levels among tested patients (males, 15.34 ± 8.50 ng/ml and females, 16.42 ± 13.55 ng/ml). Conclusion: This study demonstrated significant low Vitamin D stores (low 25-hydroxyvitamin D) in CKD patients (80.6%), who did not receive supplemental doses of Vitamin D (ergocalciferol or cholecalciferol), which was not prevented by the use of microdoses (0.5–1μg/day) of 1-hydroxyvitamin D. Furthermore, there had been significant correlation between the Vitamin D-deficient CKD patients and higher levels of PTH levels. There had been no correlation between Vitamin D deficiency among the different stages of CKD, signifying that deficiency is amenable to correction with the supplemental doses of Vitamin D even in advanced CKD patients. This study, to our knowledge, represents the first biochemical analysis of 25-hydroxyvitamin D deficiency in Libyan CKD patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded285    
    Comments [Add]    

Recommend this journal